Rochester, MNNCT06304168Now EnrollingIRB Ready

Hematopoietic and Lymphatic System Neoplasm Clinical Trial in Rochester, MN

Access cutting-edge hematopoietic and lymphatic system neoplasm treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.

Sponsored by Mayo Clinic

Quick Self-Assessment

See if you qualify for this Rochester location

Preparing your pre-screening questions…

Expert Care in Rochester

Access hematopoietic and lymphatic system neoplasm specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hematopoietic and lymphatic system neoplasm treatment provided free

Apply for This Rochester Location

Check if you qualify for this hematopoietic and lymphatic system neoplasm clinical trial in Rochester, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Rochester

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Rochester site if eligible
  4. 4Begin participation

About This Hematopoietic and Lymphatic System Neoplasm Study in Rochester

This study explores the potential value of a new blood test approach for early detection of cancer.

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Aim 1 Tissue
Patient has a biopsy confirmed diagnosis of target histology
Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.
Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without
Patient does not have the diagnosis of target histology
Aim 2 Blood
Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
Patient does not have a diagnosis of the target histology
Aim 3 Urine
Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)
Patient does not have a diagnosis of the target histology

Exclusion Criteria

Aim 1 Tissue
Cases and Controls:
Patient has had any transplants prior to tissue collection
Patient has received chemotherapy class drugs within 5 years prior to tissue collection
Patient has had radiation to the current target lesion prior to tissue collection
Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient)
Patient has bilateral breast cancer/Ductal carcinoma in situ (DCIS)
Aim 2 Blood
Cases and Controls:
Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers)
Patient has received chemotherapy class drugs in the 5 years prior to blood collection
Patient has had any prior radiation therapy to the target lesion prior to blood collection
Patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection
Patient has had an intervention to completely remove current target pathology
The current target pathology is a recurrence
Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient)
Patient has bilateral breast cancer/DCIS
Aim 3 Urine
Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers)
Patient has received chemotherapy class drugs in the 5 years prior to urine collection
Patient has had any prior radiation therapy to the target lesion prior to urine collection
Patient has had a biopsy to the target organ and/or lesion within 3 days before urine collection
The current target pathology is a recurrence
Patient has chronic indwelling urinary catheter
Patient has had a urinary tract infection within the 14 days prior to sample collection
If patient does not have a primary bladder, ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer
Patient has had an intervention to completely remove current target pathology
The current target pathology is a recurrence
Patient has multi-centric/multi-focal breast cancer with differing genetic profiles \[estrogen receptor (ER)/human epidermal growth factor receptor 2 (HER2)/progesterone receptor (PR)\] status differ; if multiple masses are present and not all are tested then exclude patient)
Patient has bilateral breast cancer/DCIS

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT06304168) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hematopoietic and Lymphatic System Neoplasm Treatment Options in Rochester, MN

If you're searching for hematopoietic and lymphatic system neoplasm treatment options in Rochester, MN, this clinical trial (NCT06304168) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hematopoietic and lymphatic system neoplasm specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hematopoietic and lymphatic system neoplasm clinical trials near you to find additional studies recruiting in your area.

More Essential Tremor Trials in Rochester, MN

See all essential tremor clinical trials recruiting in Rochester — not just this study.

Browse Essential Tremor Trials in Rochester →

Browse More Trials by Condition

Essential Tremor TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Rochester?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Rochester, MN